TME Pharma N.V. Cash Flow Conversion Efficiency
TME Pharma N.V. cash flow conversion efficiency. Based on the latest financial reports, TME Pharma N.V. (ALTME) has a cash flow conversion efficiency ratio of 0.353x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-557.00K ≈ $-651.19K USD) by net assets (€-1.58 Million ≈ $-1.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TME Pharma N.V. (2014–2025)
Cash flow conversion efficiency of TME Pharma N.V. from 2014 to 2025. This chart illustrates how TME Pharma N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALTME stock price for real-time trading data and today's change.
TME Pharma N.V. Cash Flow Conversion Ratio Explained
TME Pharma N.V. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TME Pharma N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TME Pharma N.V. ranked by their cash flow conversion efficiency. Also see market cap of TME Pharma N.V. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GLG Corp Ltd
AU:GLE
|
0.125x |
|
FingerMotion Inc
NASDAQ:FNGR
|
-0.176x |
|
Hudson Investment Group Ltd
AU:HGL
|
-0.011x |
|
Jinzhou Port Co Ltd B
SHG:900952
|
-9.376x |
|
Great Northern Minerals Ltd
AU:GNM
|
-0.073x |
|
Mount Burgess Mining NL
AU:MTB
|
0.097x |
|
Johan Holdings Bhd
KLSE:3441
|
-0.032x |
|
Quoin Pharmaceuticals Ltd DRC
NASDAQ:QNRX
|
-0.817x |
Annual Cash Flow Conversion Efficiency for TME Pharma N.V. (2014–2025)
The table below shows the annual cash flow conversion efficiency of TME Pharma N.V. from 2014 to 2025. Review financial agility of TME Pharma N.V. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-1.58 Million ≈ $-1.85 Million |
€-3.42 Million ≈ $-3.99 Million |
2.164x | +175.37% |
| 2024-12-31 | €1.61 Million ≈ $1.89 Million |
€-4.63 Million ≈ $-5.42 Million |
-2.871x | -114.98% |
| 2023-12-31 | €-294.00K ≈ $-343.72K |
€-5.63 Million ≈ $-6.59 Million |
19.167x | +100.77% |
| 2022-12-31 | €-1.27 Million ≈ $-1.49 Million |
€-12.14 Million ≈ $-14.20 Million |
9.546x | +447.13% |
| 2021-12-31 | €4.50 Million ≈ $5.26 Million |
€-12.38 Million ≈ $-14.47 Million |
-2.750x | -305.25% |
| 2020-12-31 | €7.70 Million ≈ $9.00 Million |
€-5.22 Million ≈ $-6.11 Million |
-0.679x | -129.36% |
| 2019-12-31 | €-1.85 Million ≈ $-2.17 Million |
€-4.29 Million ≈ $-5.01 Million |
2.312x | +50.67% |
| 2018-12-31 | €-2.61 Million ≈ $-3.05 Million |
€-4.00 Million ≈ $-4.68 Million |
1.534x | +41.92% |
| 2017-12-31 | €-3.92 Million ≈ $-4.58 Million |
€-4.24 Million ≈ $-4.95 Million |
1.081x | -70.15% |
| 2016-12-31 | €-2.48 Million ≈ $-2.90 Million |
€-8.99 Million ≈ $-10.51 Million |
3.622x | +88.94% |
| 2015-12-31 | €-7.03 Million ≈ $-8.22 Million |
€-13.48 Million ≈ $-15.76 Million |
1.917x | -3.93% |
| 2014-12-31 | €-6.24 Million ≈ $-7.30 Million |
€-12.46 Million ≈ $-14.57 Million |
1.996x | -- |
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more